Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Two Vortioxetine 20 mg Formulations in Healthy Subjects
NCT07624357Phase 1Completed
- Sponsor
- Adium Pharma
- Start
- Mar 2025
- Primary completion
- May 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vortioxetine in major depressive disorder (MDD) (2 arms), sponsored by Adium Pharma. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Plasma Concentration-Time Curve From Time Zero to Time t. Started Mar 2025; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07624357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07624357.